ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Court Forces CPSC To Reopen Carcinogen Policy

January 19, 1979

ACS Unveils Plan For Combating Tobacco Marketing

May 18, 1990

Xgeva Significantly Increases Bone Metastasis-Free Survival

May 27, 2011

Weak Structure, Deficiencies, Cited In Dana-Farber Reviews

November 3, 1995

NCI Rethinks Cancer Center Grants

March 14, 2014

MDV3100 Improves Survival, Reduces Death Risk by 37%

November 25, 2011